Last reviewed · How we verify
iPSC-CL
At a glance
| Generic name | iPSC-CL |
|---|---|
| Sponsor | HeartWorks, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease (PHASE1)
- Investigating Cardiovascular Adverse Events Related to Cancer Treatment
- Trikafta in Cystic Fibrosis Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- iPSC-CL CI brief — competitive landscape report
- iPSC-CL updates RSS · CI watch RSS
- HeartWorks, Inc. portfolio CI